2Bodor G S, Pot Porter S, Landt Y. Development of monoclonal antibodies for an assay of cardiac troponin-Ⅰ and preliminary results in suspected cases of myocardial infarction [ J ].Clin Chem, 1992, 38: 2203.
3La-Vecchia L, Mezzena G, Ometto R, et al. Detectable serum troponin Ⅰ in patients with heart failure of nonmyocardial ischemic origin[J]. Am J Cardiol, 1997, 80: 88.
4Vecchia L L, Mezzena G, Ometto R, et al. Detectable serum troponin Ⅰ in patients with heart failure of nonmyocardial ischemic origin[J]. Am J Cardiol, 1997, 80(1): 88.
5Adams J E, Bodor G S, Davila-Roman V G, Cardiac tropenin Ⅰ: a marker with high specificity for cardiac injury[J]. Circulation, 1993, 88: 101.
6Auerbach SR,Richmond ME,Lamour JE,et al.BNP levels predict out-come in pediatric heart failure patients post hoc analysis of the pediatriccarvedilol Tria[lJ].Circ Heart Fail,2010;3(5):606-11.
7Taub P,Xue Y,Iqbal N,et al.Mid regional pro-adrenomedullin(MR-ProADM)is superior to BNP(B-Type Natriuretic peptide)in predictingmortality in stable outpatients with stage a heart failure followed for 6years[J].J Am Coll Cardiol,2011;57(14):195.
8Pfisterer M,Buser P,Rickli H,et al.BNP-guided vs symptom-guidedheart failure therapy:the trial of intensified vs standard medical therapyin elderly patients with congestive heart failure(TIME-CHF)randomizedtria[lJ].J Am Med Ass,2009;301(4):383-92.
9Maisel A,Mueller C,Nowak R,et al.Mid-region pro-hormone markers fordiagnosis and prognosis in acute dyspnea:results from the BACH(Bio-markers in Acute Heart Failure)trial[J].J Am Coll Cardiol,2010;55(19):2062-76.
10La Vecchia L,Mezzena G,Ometto R,et al.Detectable serum troponin I inpatients with heart failure of nonmyocardial ischemic origin[J].Am JCardiol,1997;80(1):88-90.
